Skip to content
10-Q

Quarterly Report

Immuneering Corporation IMRX

0001790340-25-000061

← back to feed
Filed
May 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q1 2025 · Mar 31, 2025 $35.87M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $36.14M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.11M
Current Liabilities Q1 2025 · Dec 31, 2024 $7.5M
Total Liabilities Q1 2025 · Mar 31, 2025 $8.84M
Total Liabilities Q1 2025 · Dec 31, 2024 $11.33M
Current Assets Q1 2025 · Mar 31, 2025 $38.21M
Current Assets Q1 2025 · Dec 31, 2024 $39.59M
Total Assets Q1 2025 · Mar 31, 2025 $50.68M
Total Assets Q1 2025 · Dec 31, 2024 $52.71M
Shares Diluted Q1 2025 · Mar 31, 2024 29.37M sh
Capex Q1 2025 · Mar 31, 2024 $37.48K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$15.49M
Stockholders Equity Q1 2025 · Mar 31, 2024 $78.72M
Stockholders Equity Q1 2025 · Dec 31, 2023 $90.58M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.49
Eps Basic Q1 2025 · Mar 31, 2024 −$0.49
Sga Expense Q1 2025 · Mar 31, 2024 $4.12M
Rd Expense Q1 2025 · Mar 31, 2024 $11.2M
Net Income Q1 2025 · Mar 31, 2024 −$14.31M
Operating Income Q1 2025 · Mar 31, 2024 −$15.33M